This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers
by Aparajita Dutta
Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.
ETFs to Buy Post JNJ's Q4 Earnings Surprise & Bullish Cash Flow View
by Aparajita Dutta
JNJ beat Q4 earnings and sales estimates and sees 2026 free cash flow rising to $21B, making healthcare ETFs a safer way to play its momentum.
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan
by Aparajita Dutta
Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.
5 ETFs to Buy for January
by Sanghamitra Saha
5 ETFs to buy in January: momentum, small caps, chips, defense and healthcare shine as markets rally early in 2026 -- IWM, MTUM, SMH, XAR and IHE.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
4 Top-Ranked ETF Areas That Beat the Market in 2025
by Sanghamitra Saha
Top-ranked ETF areas that beat SPY in 2025 included semiconductors, Japan, financials and pharma. Winning ETFs were FTXL, EWJV, KBWB and IHE.
Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends
by Aparajita Dutta
XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.
Pharma's $370B Bet on America: The ETF Plays for 2026
by Aparajita Dutta
Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.
Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
by Aparajita Dutta
Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.
Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in
by Sanghamitra Saha
Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.